Egypt

The Egyptian Drug Authority (EDA) is the primary national regulatory body responsible for overseeing the registration, quality control, and market surveillance of pharmaceuticals, medical devices, diagnostics, and related health products in Egypt. Established under Law No. 151 of 2019, which replaced the Egyptian Organization for Biological Products and Vaccines (VACSERA) oversight structures and consolidated regulatory functions previously split across the Ministry of Health and Population (MoHP), the EDA operates as an independent body with a mandate to align Egyptian standards with international best practices. All health products must undergo a formal registration process before being marketed, and the EDA issues marketing authorizations based on technical dossier review, facility inspections, and product testing where required.

Applicants are required to appoint a locally registered legal representative or authorized agent in Egypt to submit and manage registration dossiers on their behalf. The EDA generally accepts submissions structured according to the Common Technical Document (CTD) format for pharmaceuticals, and has been progressively harmonizing its medical device registration requirements with Global Harmonization Task Force (GHTF) and International Medical Device Regulators Forum (IMDRF) guidelines. Notable recent reforms include the digitization of submission portals, introduction of expedited pathways for products previously approved by stringent regulatory authorities (SRAs) such as the US FDA, EMA, or Health Canada, and renewed enforcement of post-market surveillance and pharmacovigilance obligations. Egypt is also an active participant in regional harmonization efforts under the African Medicines Regulatory Harmonization (AMRH) initiative.

Public procurement of health products in Egypt is primarily coordinated through the Ministry of Health and Population (MoHP) and its affiliated entities, including the Central Administration for Pharmaceutical Affairs (CAPA) and the newly established Universal Health Insurance Authority (UHIA), which is overseeing a phased national rollout of universal health coverage beginning with pilot governorates. Centralized national tenders are the dominant mechanism for bulk procurement of pharmaceuticals, medical devices, and diagnostics for public health facilities, with the Egyptian Health Care Authority (EHCA) playing an increasing role in consolidating purchasing for public hospitals. Tender participation typically requires valid EDA registration, adherence to local pricing regulations, and compliance with MoHP technical specifications. Price controls are enforced by the EDA and the MoHP, with pharmaceutical pricing subject to formal approval processes tied to reference pricing mechanisms.

The private sector represents a substantial and growing share of health product consumption in Egypt, operating through a network of private hospitals, clinics, pharmacies, and distributors largely free from centralized tender constraints, though still subject to EDA registration and pricing oversight. Egypt also receives support through donor-funded procurement channels, including UNICEF Supply Division, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and USAID-funded programs such as the USAID Health Supply Chain program, particularly for commodities targeting HIV, tuberculosis, maternal health, and family planning. Local manufacturing is strongly encouraged by government policy, with incentives provided under the national industrial strategy and preferences embedded in certain public tender conditions favoring domestically produced goods. The Egyptian government has set strategic targets to increase local pharmaceutical and medical device manufacturing capacity, positioning Egypt as a regional production hub under its broader Vision 2030-aligned industrial development agenda.